EPOS-Iasis

EPOS-IASIS is a vibrant nano-biotechnology SME in Cyprus, established in 2006 as the First Prize Winner of the CyEntrepreneurshipCompetition (CyEC).

EPOS-IASIS (www.epos-iasis.com) is a vibrant nano-biotechnology SME in Cyprus, established in 2006 as the First Prize Winner of the CyEntrepreneurshipCompetition (CyEC). The vision of EPOS-IASIS is to become a long-standing reliable partner in health care and establish itself as a leading research, development and education enterprise in the European environment. EPOS has amassed expertise in the translational nanotheranostics, molecular imaging and cell-based technologies, with emphasis on hybrid (cell+electronics) systems, harnessing molecules and light for faster diagnosis and better prognosis. EPOS has established the sole mulrimodal In Vivo imaging platfomr on the island (mCT-3DOI-FMT) and the first setting for BRET/FRET technology in the region. It is considered a regional leader in translational nanotheranostics. In the first 13 years of life, EPOS has co-ordinated or participated as a major par in numerous national and one major FP7-IAPP and H2020 grants, bridging the academic with the entrepreneurial spirit across sectors, amassing more than 5M Euros, including MDCAs, HORIZON-WIDESPREAD-Teaming I (Precision Technologies) and FETOpen. EPOS has secured 1 EPO, 2 USPO and1 PCT patents in theranostics, new CNT-delivery systems for brain tumors and on multifunctional conjugates for metastatic Cancer. The strategy of the company is to partner with other flexible teams through the research and development phases and with well-established pharmaceutical and biomedical engineering firms for the testing, productions and selling of our products.

Recognized as a leading regional nanobiotechnology R&D SME in its field, EPOS collaborates with over 25 organisations worldwide. EPOS’s collaborators range from world-renowned academic institutions, in Europe the United States, Australia and Japan to large industrial partners, government organisations, and small and medium size enterprises that are seeking solutions to translational nanomedicine and molecular oncology problems. For example, the enterprise has strong collaborations with the National Medical and Public Health Services and the Brain Tumour Patient Association, which are supporting its research activities but are also partnering the expertise of EPOS in the establishment of a National Brain Tumour Biobank, paving the way towards advanced molecular therapeutics.

Interest and Role in the Project

In the context of the PRIME project, leading personnel with combined Clinical, Academic and Entrepreneurial expertise

In the context of the PRIME project, leading personnel with combined Clinical, Academic and Entrepreneurial expertise as well as motivated Young Researchers with notable achievements in their respective areas of expertise will be participating to materialise the objectives of the project. The group has core expertise in nanomanufacturing, nanomaterial, nanomedicine, cell and genetic technologies and will be supported by experienced business and valorisation experts. The EPOS team has a long record of successfully completed and on-going related research projects with a diversity of partners, some of which partners in PRIME assuring successful collaboration and transfer of know-how mainly to develop advanced enabling and validating models (e.g.3D biomimetic tumour organoids, orthotopic animal models), 3D stem cell constructs (bioengineering), and designing and implementing the biological aspects of In Vitro validation and the final proof-of-concept integration activities, the most important part towards the proposed implants. Through its well-structured collaboration networks will contribute significantly to ecosystem building and informal training.